S&P 500   4,267.21 (-0.88%)
DOW   33,931.85 (-0.64%)
QQQ   328.60 (-1.11%)
AAPL   173.88 (+0.49%)
MSFT   291.65 (-0.36%)
META   175.90 (-1.99%)
GOOGL   120.36 (-1.10%)
AMZN   141.91 (-1.98%)
TSLA   906.57 (-1.43%)
NVDA   183.44 (-2.83%)
NIO   20.40 (-2.44%)
BABA   91.17 (-1.60%)
AMD   97.61 (-2.58%)
MU   61.33 (-3.96%)
T   18.42 (-0.81%)
CGC   4.23 (+11.90%)
F   16.17 (-1.58%)
GE   79.98 (-1.34%)
DIS   123.86 (-0.88%)
AMC   23.67 (-4.59%)
PYPL   100.19 (-1.85%)
PFE   49.50 (-0.72%)
NFLX   240.70 (-2.03%)
S&P 500   4,267.21 (-0.88%)
DOW   33,931.85 (-0.64%)
QQQ   328.60 (-1.11%)
AAPL   173.88 (+0.49%)
MSFT   291.65 (-0.36%)
META   175.90 (-1.99%)
GOOGL   120.36 (-1.10%)
AMZN   141.91 (-1.98%)
TSLA   906.57 (-1.43%)
NVDA   183.44 (-2.83%)
NIO   20.40 (-2.44%)
BABA   91.17 (-1.60%)
AMD   97.61 (-2.58%)
MU   61.33 (-3.96%)
T   18.42 (-0.81%)
CGC   4.23 (+11.90%)
F   16.17 (-1.58%)
GE   79.98 (-1.34%)
DIS   123.86 (-0.88%)
AMC   23.67 (-4.59%)
PYPL   100.19 (-1.85%)
PFE   49.50 (-0.72%)
NFLX   240.70 (-2.03%)
S&P 500   4,267.21 (-0.88%)
DOW   33,931.85 (-0.64%)
QQQ   328.60 (-1.11%)
AAPL   173.88 (+0.49%)
MSFT   291.65 (-0.36%)
META   175.90 (-1.99%)
GOOGL   120.36 (-1.10%)
AMZN   141.91 (-1.98%)
TSLA   906.57 (-1.43%)
NVDA   183.44 (-2.83%)
NIO   20.40 (-2.44%)
BABA   91.17 (-1.60%)
AMD   97.61 (-2.58%)
MU   61.33 (-3.96%)
T   18.42 (-0.81%)
CGC   4.23 (+11.90%)
F   16.17 (-1.58%)
GE   79.98 (-1.34%)
DIS   123.86 (-0.88%)
AMC   23.67 (-4.59%)
PYPL   100.19 (-1.85%)
PFE   49.50 (-0.72%)
NFLX   240.70 (-2.03%)
S&P 500   4,267.21 (-0.88%)
DOW   33,931.85 (-0.64%)
QQQ   328.60 (-1.11%)
AAPL   173.88 (+0.49%)
MSFT   291.65 (-0.36%)
META   175.90 (-1.99%)
GOOGL   120.36 (-1.10%)
AMZN   141.91 (-1.98%)
TSLA   906.57 (-1.43%)
NVDA   183.44 (-2.83%)
NIO   20.40 (-2.44%)
BABA   91.17 (-1.60%)
AMD   97.61 (-2.58%)
MU   61.33 (-3.96%)
T   18.42 (-0.81%)
CGC   4.23 (+11.90%)
F   16.17 (-1.58%)
GE   79.98 (-1.34%)
DIS   123.86 (-0.88%)
AMC   23.67 (-4.59%)
PYPL   100.19 (-1.85%)
PFE   49.50 (-0.72%)
NFLX   240.70 (-2.03%)
OTCMKTS:PVCT

Provectus Biopharmaceuticals - PVCT Stock Forecast, Price & News

$0.06
0.00 (0.00%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.05
$0.06
50-Day Range
$0.05
$0.06
52-Week Range
$0.04
$0.07
Volume
358,100 shs
Average Volume
141,506 shs
Market Capitalization
$23.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PVCT stock logo

About Provectus Biopharmaceuticals (OTCMKTS:PVCT) Stock

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.

Receive PVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PVCT Stock News Headlines

AtScale Named Snowflake Premier Partner
See More Headlines
Receive PVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PVCT Company Calendar

Today
8/17/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PVCT
Previous Symbol
NYSEMKT:PVCT
Employees
2
Year Founded
N/A

Profitability

Net Income
$-5,540,000.00
Pretax Margin
-863.22%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.01) per share

Miscellaneous

Free Float
383,001,000
Market Cap
$23.07 million
Optionable
Not Optionable
Beta
0.18

Key Executives

  • Dr. Eric A. Wachter (Age 59)
    Co-Founder & CTO
    Comp: $170.8k
  • Ms. Heather Raines CPA (Age 55)
    Chief Financial Officer
    Comp: $83.33k
  • Mr. Bruce Horowitz (Age 66)
    COO & Director
    Comp: $244.6k













PVCT Stock - Frequently Asked Questions

How have PVCT shares performed in 2022?

Provectus Biopharmaceuticals' stock was trading at $0.0550 on January 1st, 2022. Since then, PVCT shares have increased by 0.0% and is now trading at $0.0550.
View the best growth stocks for 2022 here
.

Are investors shorting Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 500 shares, an increase of 400.0% from the July 15th total of 100 shares. Based on an average daily volume of 306,000 shares, the short-interest ratio is presently 0.0 days.
View Provectus Biopharmaceuticals' Short Interest
.

What other stocks do shareholders of Provectus Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), Cytori Therapeutics (CYTX), (DARA) (DARA), Energy Transfer (ET), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB) and MaxLinear (MXL).

What is Provectus Biopharmaceuticals' stock symbol?

Provectus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "PVCT."

How do I buy shares of Provectus Biopharmaceuticals?

Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provectus Biopharmaceuticals' stock price today?

One share of PVCT stock can currently be purchased for approximately $0.06.

How much money does Provectus Biopharmaceuticals make?

Provectus Biopharmaceuticals (OTCMKTS:PVCT) has a market capitalization of $23.07 million. The company earns $-5,540,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis.

How can I contact Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals' mailing address is 10025 INVESTMENT DRIVE SUITE 250, KNOXVILLE TN, 37932. The official website for the company is www.provectusbio.com. The company can be reached via phone at (866) 594-5999, via email at investorrelations@pvct.com, or via fax at 866-998-0005.

This page (OTCMKTS:PVCT) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.